See more : Verra Mobility Corporation (VRRM) Income Statement Analysis – Financial Results
Complete financial analysis of Allgens Medical Technology CO., LTD. (688613.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allgens Medical Technology CO., LTD., a leading company in the Medical – Devices industry within the Healthcare sector.
- Econocom Group SE (ECONB.BR) Income Statement Analysis – Financial Results
- Hersha Hospitality Trust (HT-PD) Income Statement Analysis – Financial Results
- Marks Electrical Group PLC (MRK.L) Income Statement Analysis – Financial Results
- Grandsys Inc. (6910.TWO) Income Statement Analysis – Financial Results
- Henan Dayou Energy Co., Ltd (600403.SS) Income Statement Analysis – Financial Results
Allgens Medical Technology CO., LTD. (688613.SS)
About Allgens Medical Technology CO., LTD.
Allgens Medical Technology CO., LTD., a medical device company, develops and manufactures platforms of biomimetic synthetic bone grafts for use in regions of compromised cancellous and cortical bone worldwide. The company offers BonGold mineralized collagen scaffold bone graft; Alligator high performance bone marrow aspirator; and OssaNova mineralized collagen-based bone filling augmentation material. Its products are used in various skeletal applications in and around the human skeleton. Allgens Medical Technology CO., LTD. was founded in 2004 and is based in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 226.48M | 245.31M | 236.06M | 183.76M | 168.59M | 123.69M | 91.38M |
| Cost of Revenue | 39.24M | 40.78M | 34.58M | 29.76M | 28.85M | 20.81M | 18.59M |
| Gross Profit | 187.24M | 204.53M | 201.49M | 154.00M | 139.74M | 102.88M | 72.79M |
| Gross Profit Ratio | 82.67% | 83.38% | 85.35% | 83.81% | 82.88% | 83.18% | 79.66% |
| Research & Development | 45.50M | 57.46M | 33.23M | 16.01M | 22.49M | 18.02M | 12.36M |
| General & Administrative | 50.49M | 8.78M | 4.17M | 4.39M | 14.24M | 26.44M | 13.90M |
| Selling & Marketing | 37.69M | 31.27M | 23.08M | 11.50M | 15.63M | 13.26M | 9.42M |
| SG&A | 88.18M | 40.05M | 27.25M | 15.89M | 29.87M | 39.71M | 23.32M |
| Other Expenses | 4.56M | 23.75M | 20.26M | 22.71M | 25.24M | -549.35K | -361.98 |
| Operating Expenses | 138.24M | 121.26M | 80.75M | 54.61M | 77.60M | 69.12M | 45.02M |
| Cost & Expenses | 177.48M | 162.04M | 115.32M | 84.37M | 106.45M | 89.93M | 63.61M |
| Interest Income | 3.27M | 5.59M | 4.28M | 127.53K | 497.20K | 1.72M | 93.38K |
| Interest Expense | 3.15M | 1.87M | 3.42M | 1.28M | 1.03M | 0.00 | 310.62K |
| Depreciation & Amortization | 19.96M | 20.31M | 14.01M | 12.72M | 11.59M | 8.04M | 4.30M |
| EBITDA | 69.28M | 118.37M | 148.64M | 111.92M | 87.46M | 42.29M | 32.08M |
| EBITDA Ratio | 30.59% | 43.53% | 57.54% | 60.90% | 43.74% | 32.91% | 35.81% |
| Operating Income | 48.99M | 96.32M | 134.91M | 102.19M | 74.45M | 34.80M | 27.47M |
| Operating Income Ratio | 21.63% | 39.26% | 57.15% | 55.61% | 44.16% | 28.13% | 30.06% |
| Total Other Income/Expenses | 100.16K | -114.80K | -2.86M | -110.42K | 104.58K | -549.35K | 2.00 |
| Income Before Tax | 49.09M | 96.20M | 132.05M | 102.08M | 74.55M | 34.25M | 27.47M |
| Income Before Tax Ratio | 21.68% | 39.22% | 55.94% | 55.55% | 44.22% | 27.69% | 30.06% |
| Income Tax Expense | -3.87M | 4.50M | 13.98M | 14.96M | 10.36M | 6.74M | 3.94M |
| Net Income | 54.23M | 95.22M | 120.78M | 88.94M | 67.78M | 32.99M | 23.53M |
| Net Income Ratio | 23.95% | 38.82% | 51.17% | 48.40% | 40.21% | 26.67% | 25.75% |
| EPS | 0.41 | 0.71 | 0.91 | 0.67 | 0.51 | 0.34 | 0.29 |
| EPS Diluted | 0.41 | 0.71 | 0.91 | 0.67 | 0.51 | 0.34 | 0.29 |
| Weighted Avg Shares Out | 132.27M | 133.33M | 133.33M | 133.33M | 133.33M | 97.01M | 81.14M |
| Weighted Avg Shares Out (Dil) | 132.27M | 133.33M | 133.33M | 133.33M | 133.33M | 97.01M | 81.14M |
Source: https://incomestatements.info
Category: Stock Reports